Apolipoprotein A−I human
SIGMA/SRP4693 - recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)
Synonym: APOA1; Apo-AI; Apolipoprotein A-I; C117399; MGC117399
CAS Number: 1426185-50-3
Product Type: Chemical
| assay | ≥97% (HPLC) |
| ≥97% (SDS-PAGE) | |
| biological source | human |
| form | lyophilized |
| impurities | endotoxin, tested |
| mol wt | ~28 kDa |
| NCBI accession no. | NM_000039   |
| packaging | pkg of 100 μg |
| recombinant | expressed in E. coli |
| shipped in | wet ice |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| UniProt accession no. | P02647 |
| Application: | Apolipoprotein A-I human has been used in the cholesterol efflux assay. |
| Biochem/physiol Actions: | ApoA-I (apolipoprotein A-I), which is found exclusively in HDL (high-density lipoprotein), has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is thought to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases. Changes in the level of serum apoA-I may serve as a prognostic marker for non-metastatic nasopharyngeal carcinoma. Low levels of apoA-I in the plasma is linked to hyperhomocysteinemia. |
| General description: | ApoA-I (apolipoprotein A-I) is a 29.0kDa protein produced in the liver and intestine, and secreted as the predominant constituent of nascent high-density lipoprotein (HDL) particle. Recombinant human ApoA-I is a 28.2kDa protein of 244 amino acid residues. |
| General description: | ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases. |
| Physical form: | Sterile filtered and Lyophilized without additives. |
| Preparation Note: | Centrifuge the vial prior to opening. Avoid freeze-thaw cycles. |
| Reconstitution: | Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4 °C for 1 week or –20 °C for future use. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (HPLC); ≥97% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |